Up next

A CDMO Roundtable: The Making of a Molecule: Peptide Synthesis

Mimoun Ayoub, PhD, Senior Vice President and Global Commercial Head of Peptides, CordenPharma
Alaric Desmarchelier, PhD, Business Development Manager, Peptides, Almac Sciences

The blockbuster success of the GLP-1 agonists and related drugs has renewed interest in peptide-based drugs, but how is the manufacturing technology evolving? In a CDMO roundtable, industry experts share their perspectives on the latest in peptide synthesis featuring Alaric Desmarchelier, PhD, Business Development Manager, Peptides, Almac Sciences, Mimoun Ayoub, PhD, Senior Vice President and Global Commercial Head of Peptides, CordenPharma, Matt Bio, PhD, Chief Scientific Officer, Cambrex, and Eric Fang, PhD, General Manager, Snapdragon Chemistry, Cambrex.

Matt Bio, PhD, Chief Scientific Officer, Cambrex
Eric Fang, PhD, General Manager, Snapdragon Chemistry, Cambrex

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

For a full list of the 2026 podcast episode schedule, click here.

You May Also Like

Biomanufacturing: Capacity Trends & CDMO Insights

By
Sponsored by Lonza AG What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand…

Beyond ADCs: Next-Generation Drug Conjugates

By
Sponsored by Lonza AG Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative to antibody drug conjugates (ADCs),…

New Excipient Products: Are They Coming?

By
Innovation in excipients is important to optimize a drug formulation, but there are barriers to innovation, including regulatory barriers, which excipient manufacturers and users are seeking to address. Providing the…

Pipeline Potential: Small-Molecule Drugs

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…